BioNexus Gene Lab Corp
BGLC
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.8M
Close$
$-0.79
153.6% downside
Current Fair Value
153.6% downsideOvervalued by 153.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.80 Million |
|---|---|
| Enterprise Value | $2.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.61 |
| Beta | 2.21 |
| Outstanding Shares | 2,417,314 |
Return
| Return on Equity | -33.11% |
|---|---|
| Return on Assets | -29.51% |
| Return on Invested Capital | -32.41% |
Valuation & Multiples
| P/E Ratio | -1.25 |
|---|---|
| PEG | 2.33 |
| Price to Sales | 1.47 |
| Price to Book Ratio | 0.49 |
| Enterprise Value to Revenue | 0.89 |
| Enterprise Value to EBIT | -1.08 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.60%▲ 0.59% |
|---|---|
| Total Invested | $27,199▲ 5372.64% |
| Investors Holding | 3▲ 1.00% |
ESG Score
No data